Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Global President TAVR & Surg | August 18, 2025 | August 18, 2025 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director · President, CEO | August 07, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date August 18, 2025 · Filed August 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,900.3913 |
Ending reported balance
After 2025-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-08-18 · Exercise / conversion · Acquired 8,950 · Balance 215,850.3913 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. Row 2 · 2025-08-18 · Sale · Disposed 8,950 · Balance 206,900.3913 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.68 to $78.43. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $59.26 · Expires 2026-05-07 | Direct | 35,800 |
Reported balance
After 2025-08-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-18 · Exercise / conversion · Disposed 8,950 · Balance 35,800 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 148.1703 |
Reported balance
Holding disclosure · report date 2025-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 148.1703 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.68 to $78.43. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
PROCEPT BioRobotics Corp
Report date August 07, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThe Larry Wood Trust | 23,900 |
Reported balance
After 2026-08-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 23,900 · Balance 23,900 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.67 to $21.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 314,203 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 314,203 F2: Includes 825 shares acquired on May 14, 2026, under the Issuer's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.67 to $21.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2: Includes 825 shares acquired on May 14, 2026, under the Issuer's 2021 Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2019 Filed Feb 5, 2019 11:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-001757 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,168 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 11:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $169.10 | $1,135,675.60 |
DisclosureSEC source: 0001225208-19-001757 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 11:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-001757 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,365.8685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-000698 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,884 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $148.15 | $994,975.40 |
DisclosureSEC source: 0001225208-19-000698 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-000698 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,365.8685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-016825 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $162.66 | $1,024,758.00 |
DisclosureSEC source: 0001225208-18-016825 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-016825 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,949.8685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-015563 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $147.96 | $932,148.00 |
DisclosureSEC source: 0001225208-18-015563 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-015563 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,949.8685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 21:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-014652 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,600 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 21:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $142.64 | $898,632.00 |
DisclosureSEC source: 0001225208-18-014652 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 21:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-014652 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,949.8685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 23:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-013508 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 23:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $146.95 | $925,785.00 |
DisclosureSEC source: 0001225208-18-013508 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 23:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-013508 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,949.8685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-012711 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 1, 2017. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $136.73 | $861,399.00 |
DisclosureSEC source: 0001225208-18-012711 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 1, 2017. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-012711 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,949.8685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 1, 2017. Read SEC document |
| July 16, 2018 Filed Jul 16, 2018 22:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-011712 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| July 16, 2018 Filed Jul 16, 2018 22:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $148.02 | $932,526.00 |
DisclosureSEC source: 0001225208-18-011712 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| July 16, 2018 Filed Jul 16, 2018 22:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-011712 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,949.8685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 23:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 564 | $146.99 | $82,902.36 |
DisclosureSEC source: 0001225208-18-011638 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-010776 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,800 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $151.86 | $956,718.00 |
DisclosureSEC source: 0001225208-18-010776 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,155.9644 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-010776 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,455.9644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009679 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2025-05-16 F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 21,600 | $0.00 Strike: $135.83 | $0.00 |
DisclosureSEC source: 0001225208-18-009679 · doc4.xml · derivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,600 Underlying: Common Stock · 21,600 shares Expires 2025-05-16 F3 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009679 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,155.9644 F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 9,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009583 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,362 shares Expires 2018-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.exercise_date: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.underlying_shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 4,642 | $136.43 | $633,308.06 |
DisclosureSEC source: 0001225208-18-009583 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,655.9644 F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 9,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009583 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,297.9644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-009494 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,100 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $137.26 | $864,738.00 |
DisclosureSEC source: 0001225208-18-009494 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,935.9644 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-009494 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,235.9644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,066 | $138.11 | $147,225.26 |
DisclosureSEC source: 0001225208-18-009494 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,935.9644 F1 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-007854 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,400 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $138.97 | $875,511.00 |
DisclosureSEC source: 0001225208-18-007854 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,001.9644 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-007854 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,301.9644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-006439 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,700 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $141.49 | $891,387.00 |
DisclosureSEC source: 0001225208-18-006439 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,848.4338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 00:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-006439 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,148.4338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 21:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-003589 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 21:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $134.27 | $845,901.00 |
DisclosureSEC source: 0001225208-18-003589 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,848.4338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 21:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-003589 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,148.4338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 01:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-001183 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,300 Underlying: Common Stock · 6,300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 01:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,300 | $121.00 | $762,300.00 |
DisclosureSEC source: 0001225208-18-001183 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,848.4338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 01:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,300 | $42.73 | $269,167.50 |
DisclosureSEC source: 0001225208-18-001183 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,148.4338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.